GlyConMedics welcomes interested potential investors to contact the company at firstname.lastname@example.org. This does constitute the offer of securities. Investors should be either professional investors or meet the definition of a sophisticated investor.
Due to the specific synergy between OZ101 and the sulphonylurea class of anti-diabetes drugs, the initial target market will comprise patients who are using sulphonylurea monotherapy to treat their diabetes.
The total global annual sales of anti-diabetes medications, excluding insulin, has been reported to be approximately US$ 32.1 billion in 2010, of which ~16 billion is generated in the USA. The sulphonylurea class of anti-diabetes drugs are off-patent and generate annual sales of US$ 1.14 billion. Sulphonylureas are the most widely used anti-diabetes drugs for treating type 2 diabetes in countries with the largest number of diabetic patients (i.e. China, India and Indonesia), with near-half of the patients taking this class of drugs. Approximately quarter of the type 2 diabetes patients in USA prescribed with sulphonylurea. Read More>>>
Diabetes as a global major health crisis
Type 2 diabetes mellitus is the world’s fastest growing chronic disease. Each year 7 million people develop diabetes and 3.8 million deaths are attributable to diabetes. According to the International Diabetic Federation the number of individuals with diabetes will increase from 415 million in 2015 to 642 million by 2040. It is also estimated that currently over 200 million diabetic individuals remain undiagnosed. Thus, due to an increased prevalence of pre-diabetic dysglycaemia, a large number of individuals are at risk of developing type 2 diabetes mellitus, particularly due to genetic predisposition, life style factors and obesity.
On 20 December 2006 the United Nations General Assembly passed United Nation Resolution 61/225 recognizing diabetes as a major health crisis facing all nations of the world. The Resolution designates 14 November each year as the United Nations “World Diabetes Day” and calls on all nations to develop national policies for the prevention, treatment and care of people living with diabetes and those at risk of developing diabetes.
The International Diabetes Federation report indicates very large diabetes management costs in:
USA $320 billion (in 2010 alone for acute hospitalization and caring costs etc...)
Australia $14.6 billion (in 2010 alone for productivity loss, acute hospitalisation and caring costs etc...)
The World Health Organisation estimated a loss of National Income between 2005 and 2014 due to diabetes in:
China $555.7 billion India $336.6 billion Russian Federation $303.2 billion Brazil $49.2 billion
Diabetes is the fourth leading cause of global mortality by disease. The global burden of diabetes is increasing sharply as a result of an evolving diabetes pandemic.
Type 2 diabetes is the sixth leading cause of death in Australia. According to Diabetes Australia, an estimated 280 Australians develop diabetes every day. The 2013 total number of Australians diagnosed with diabetes was ~1,648,860 but it is estimated that a further 814,540 individuals have diabetes but are undiagnosed. According to the International Diabetes Federation diabetes atlas, approximately ~7% of the Australians population currently diagnosed with type 2 diabetes. These facts indicate that diabetes is occurring at an alarming rate and is out-of-control. Up to 60% of cases of type 2 diabetes can be prevented by good blood glucose control and maintaining a healthy lifestyle can significantly reduce the complications associated with diabetes. Read More>>> .
In 2015, the International Diabetes Federation, Diabetes Atlas reported that the top 6 countries for people with diabetes were:
China (109.6 million)
India (69.2 million)
USA (29.3 million)
Brazil (14.3 million)
Russian Federation (12.1 million)
Mexico (11.5 million)
According to International Diabetes Federation over half of diabetes patients reside in just 3 countries, USA, China and India (See Table 1). Read More>>>